LRRC15 leucine rich repeat containing 15
ENSG00000172061 · protein coding · Open Targets profile
(Microbial infection) Modulates the ability of SARS-CoV-2 to infect host cells through interaction with the spike protein (PubMed:36228039, PubMed:36735681, PubMed:36757924). Does not act as a SARS-CoV-2 entry receptor but sequesters virions and antagonizes in trans SARS-CoV-2 infection of ACE2(+) cells when expressed on nearby cells (PubMed:36228039, PubMed:36757924). {ECO:0000269|PubMed:36228039, ECO:0000269|PubMed:36735681, ECO:0000269|PubMed:36757924}.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Antibody
- UniProt loc high conf, GO CC high conf, UniProt SigP or TMHMM, Human Protein Atlas loc
gnomAD loss of function constraint: o/e 1.1613999605178833 (upper bound 2.441999912261963). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
No named investigators on registry trials of LRRC15's approved or late-stage drugs in the last three years.
No terminated, withdrawn or suspended trials of LRRC15's drugs are registered
All 0 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.
| Drug | Type | Highest stage | Indications | Source records |
|---|---|---|---|---|
| No drugs or clinical candidates recorded. | ||||